Develops therapies for cancer treatment, focusing on targeting dysregulated transcription factors to inhibit tumor growth.
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering advancements in cancer therapeutics. Specializing in dysregulated transcription factors, Kronos Bio focuses on unraveling the intricate networks that drive oncogenic activities. Their innovative product pipeline is anchored by entospletinib, an orally administered, selective inhibitor of spleen tyrosine kinase. This promising candidate is currently undergoing a registrational phase 3 clinical trial, evaluating its efficacy in combination with induction chemotherapy for acute myeloid leukemia patients harboring NPM1 mutations.
In addition to entospletinib, Kronos Bio is advancing KB-0742, an orally bioavailable inhibitor targeting cyclin dependent kinase 9. This compound is aimed at treating MYC-amplified solid tumors and is currently progressing through a phase 1/2 clinical trial. Further expanding their therapeutic portfolio, Kronos Bio is developing Lanraplenib, a next-generation SYK inhibitor intended for the treatment of autoimmune diseases.
Founded in 2017 and headquartered in San Mateo, California, Kronos Bio, Inc. exemplifies a commitment to innovation in oncology, striving to bring novel treatments to patients grappling with cancer and related conditions.